Initial Public Offering
Baird served as a book-runner on this offering
AboutQuotient Limited (“Quotient” or the “Company”) (NASDAQ: QTNTU) recently completed an initial public offering of 5,000,000 units, at a price of $8.00 per unit, generating gross proceeds of approximately $40 million. The Company intends to use the net proceeds from the offering to invest on the conversion of the MosaiQ manufacturing facility and the installation of the initial manufacturing system for consumables, for the development of the initial MosaiQ consumables and instrument, and for general corporate purposes.
Quotient is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests for blood grouping and serological disease screening. Quotient is developing MosaiQ, its proprietary technology platform, to offer a breadth of diagnostic tests that is unmatched by any commercially available transfusion diagnostic instrument platform. The Company's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins (near Geneva), Switzerland.
For additional information about this transaction, please contact:
- April 2014
- Quotient Limited
- Target Location